Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dive deep into Lymphedema's genetic roots

NCT ID NCT05629026

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand why lymphedema develops by comparing gene activity in swollen versus healthy limbs. Researchers will take tiny tissue samples from 60 adults with primary or secondary lymphedema. The goal is to identify molecular differences that could point toward future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal key molecular targets for future lymphedema treatments.
What could go wrong
This is an early observational study with only 60 participants, so findings may not lead directly to therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients in who developed primary lymphedema or secondary lymphedema after breast cancer treatment. 2. Male and female over the age of 18 and under 75. 3. Patient affiliated to a social security scheme in France. 4. Patient having signed informed consent prior to inclusion in the study and prior to any specific procedure for the study. 5. Patients with no recidive \> 3 years after cancer surgery. 6. Patients with Body Mass Index \<35. 7. Patient enrolled in a care pathway for the management of their lymphedema (medical and educational care). 8. Patients wearing a compression orthosis on the limb with lymphedema. Exclusion Criteria: 1. Patients with strong suspicion or with active bacterial or fungal infection. 2. Patient with venous insufficiency associated with lymphedema. 3. Patient with a history of deep venous thrombosis on the limb with lymphedema. 4. History of chronic inflammatory disease. 5. Active neoplasia during parallel management. 6. Patient already included in another therapeutic trial. 7. Pregnant or breastfeeding woman. 8. Metastatic cancer. 9. Bilateral breast cancer. 10. Obliterative arterial disease. 11. Multiple erysipelas. 12. Active smoking (delayed healing). 13. Medicines that may promote delayed healing (Corticosteroid therapy, immunosuppressants). 14. Medication that thins the blood (aspirin and antiplatelet agent, anti-coagulant). 15. Betadine allergy. 16. Patient under guardianship or trusteeship, persons placed under the protection of justice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphedema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lymphedema primary lymphedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphedema

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Toulouse Hospital

    RECRUITING

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.